Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

RAGE has potential pathogenetic and prognostic value in non-intubated hospitalized patients with COVID-19

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Identifying dominant-negative actions of a dopamine transporter variant in patients with parkinsonism and neuropsychiatric disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R-dependent manner

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Asymmetric cell division promotes therapeutic resistance in glioblastoma stem cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Local complement activation is associated with primary graft dysfunction after lung transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Longitudinal analysis of naturally acquired PfEMP1 CIDR domain variant antibodies identifies associations with malaria protection

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Enabling timely HIV postexposure prophylaxis access in sub-Saharan Africa

    Research output: Contribution to journalLetterResearchpeer-review

  2. Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Development and Validation of a Risk Score for Post-Transplant Lymphoproliferative Disorders among Solid Organ Transplant Recipients

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Katherine D Wick
  • Lianne Siegel
  • James D Neaton
  • Cathryn Oldmixon
  • Jens Lundgren
  • Robin L Dewar
  • H Clifford Lane
  • B Taylor Thompson
  • Michael A Matthay
View graph of relations

BackgroundThe value of the soluble receptor for advanced glycation end-products (sRAGE) as a biomarker in COVID-19 is not well understood. We tested the association between plasma sRAGE and illness severity, viral burden, and clinical outcomes in hospitalized patients with COVID-19 who were not mechanically ventilated.MethodsBaseline sRAGE was measured among participants enrolled in the ACTIV-3/TICO trial of bamlanivimab for hospitalized patients with COVID-19. Spearman's rank correlation was used to assess the relationship between sRAGE and other plasma biomarkers, including viral nucleocapsid antigen. Fine-Gray models adjusted for baseline supplemental oxygen requirement, antigen level, positive endogenous anti-nucleocapsid antibody response, sex, age, BMI, diabetes mellitus, renal impairment, corticosteroid treatment, and log2-transformed IL-6 level were used to assess the association between baseline sRAGE and time to sustained recovery. Cox regression adjusted for the same factors was used to assess the association between sRAGE and mortality.ResultsAmong 277 participants, baseline sRAGE was strongly correlated with viral plasma antigen concentration (ρ = 0.57). There was a weaker correlation between sRAGE and biomarkers of systemic inflammation, such as IL-6 (ρ = 0.36) and CRP (ρ = 0.20). Participants with plasma sRAGE in the highest quartile had a significantly lower rate of sustained recovery (adjusted recovery rate ratio, 0.64 [95% CI, 0.43-0.90]) and a higher unadjusted risk of death (HR, 4.70 [95% CI, 2.01-10.99]) compared with participants in the lower quartiles.ConclusionElevated plasma sRAGE in hospitalized, nonventilated patients with COVID-19 was an indicator of both clinical illness severity and plasma viral load. Plasma sRAGE in the highest quartile was associated with a lower likelihood of sustained recovery and higher unadjusted risk of death. These findings, which we believe to be novel, indicate that plasma sRAGE may be a promising biomarker for COVID-19 prognostication and clinical trial enrichment.Trial RegistrationClinicalTrials.gov NCT04501978.FundingNIH (5T32GM008440-24, 18X107CF6, HHSN261201500003I, R35HL140026, and OT2HL156812).

Original languageEnglish
Article numbere157499
JournalJCI Insight
Volume7
Issue number9
ISSN2379-3708
DOIs
Publication statusPublished - 9 May 2022

    Research areas

  • Antibodies, Monoclonal, Humanized, Antibodies, Neutralizing, Biomarkers, COVID-19, Humans, Interleukin-6, Prognosis, Receptor for Advanced Glycation End Products

ID: 75683339